Hsbc Holdings PLC Has $88.23 Million Position in Kenvue Inc. $KVUE

Hsbc Holdings PLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 31.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,106,368 shares of the company’s stock after acquiring an additional 1,230,957 shares during the period. Hsbc Holdings PLC owned approximately 0.27% of Kenvue worth $88,231,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Elyxium Wealth LLC bought a new position in shares of Kenvue during the fourth quarter worth $26,000. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. MV Capital Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at about $28,000. Reflection Asset Management bought a new stake in Kenvue during the 4th quarter worth approximately $32,000. Finally, SBI Securities Co. Ltd. lifted its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.59% of the stock is owned by insiders.

Kenvue Stock Performance

KVUE opened at $18.17 on Monday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The company has a market capitalization of $34.88 billion, a PE ratio of 21.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.54. The business has a fifty day simple moving average of $17.54 and a 200 day simple moving average of $17.57.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.24 EPS. Research analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.6%. Kenvue’s dividend payout ratio is currently 97.65%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Barclays cut their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Finally, Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.